$NTHI

Heshmatpour Amir F purchased $50K of NTHI

Heshmatpour Amir F (CEO, President) purchased 9,000 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at $5.54 on 2026-08-18.

Original reporting
SEC EDGAR · Heshmatpour Amir F
Published Aug 18, 2026, 6:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 6:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTHI
Bullish
low confidence
Mentioned
$NTHI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTHIBullishLow
01

Why it matters

The disclosed open-market purchase by the CEO/President is a new, primary-source datapoint but does not include any new company fundamentals (guidance, contracts, litigation, or financial results).

02

Market read

Traders may note the insider buying as a small sentiment input, but it is unlikely to drive a durable repricing without additional company catalysts.

03

What to watch

The article does not state whether the purchase was part of a broader pattern, nor does it provide context on total insider holdings changes beyond the post-transaction share count.

Relevance 4/10Novelty 3/10Timing: today’s SEC Form 4 filing (2026-08-18)

Background

The article is an SEC Form 4 insider transaction disclosure for NEONC Technologies Holdings, Inc.

Company-level read

Ticker impact

$NTHIBullishLow confidence
Context

SEC Form 4 shows CEO/President Heshmatpour Amir F bought 9,000 shares of NEONC Technologies Holdings at $5.54 on 2026-08-18.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and should fade unless followed by larger actions or company-specific news.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan and no accompanying operational or financial disclosure in the text.

Market effects

No sector-level implications are provided; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Insider buys can be driven by diversification, liquidity needs, or routine compensation-related behavior, so the signal may be weak.

Key entities

  • NEONC Technologies Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Heshmatpour Amir F

    CEO, President, and 10% owner who purchased shares on 2026-08-18.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTHIMed

Stonegate, Inc.: Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

Stonegate Capital Partners updated coverage of NeOnc Technologies Holdings (NASDAQ: NTHI), citing 2Q26 progress for NEO100 and NEO212. NEO100 Phase 2a reported PFS at 6 months of 48.9% vs a 20% benchmark (p=0.0047), median OS 26.09 months, and no major toxicities. NeOnc plans a Type B FDA meeting; R&D rose to $2.6M from $0.7M year over year.

$NTHIMed

WallStreet-PR: NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Holdings (NASDAQ: NTHI) reported Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. It said six-month progression-free survival was 48.9% versus a 20% historical benchmark, with p=0.0047. Median overall survival was about 26 months, with no major toxicities. NeOnc plans an FDA meeting on next trial steps.

$NTHIMedAI 8/10

NeOnc Technologies Reports Positive Topline Data Of NEO100 Phase 2a Study, Stock Up In Pre-Market

NeOnc Technologies Holdings (NTHI) reported positive topline Phase 2a results for intranasal NEO100 (NEO100-01) in IDH1-mutant Grade IV glioma or Grade III astrocytoma. In 24 patients at 1,152 mg/day, six-month progression-free survival was 48.9% vs 20% expected. Median overall survival was 26.09 months. Company plans an FDA Type B meeting and will present full safety data.

$NTHIHighAI 9/10

Why is Neonc Technologies stock surging today?

Investing.com reports Neonc Technologies Holdings Inc (NTHI) shares rose 11.3% pre-open after its Phase 2a NEO100-01 intranasal NEO100 study in Grade III/IV IDH1-mutant glioma met the primary endpoint. Six-month progression-free survival was 48.9% vs a 20% benchmark (p=0.0047) in 24 patients. Company discussed efficacy, safety, and next regulatory steps.

$NTHIMedAI 8/10

NeOnc Technologies stock jumps on positive glioma trial data

NeOnc Technologies Holdings (NASDAQ:NTHI) shares rose 11.7% after positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The study met its primary endpoint with 6-month progression-free survival of 48.9% vs a 20% benchmark (p=0.0047). Median overall survival was 26.09 months; 86.7% were alive at six months. The company plans an FDA Type B meeting.